首页 | 本学科首页   官方微博 | 高级检索  
检索        

抗VEGF药物治疗新生血管性眼病的研究进展
引用本文:陈丹,樊映川,李丽英.抗VEGF药物治疗新生血管性眼病的研究进展[J].国际眼科杂志,2008,8(1):123-125.
作者姓名:陈丹  樊映川  李丽英
作者单位:1. 成都中医药大学,中国四川省成都市,610075
2. 四川省人民医院眼科,中国四川省成都市,610072
摘    要:血管内皮生长因子(vascular endothelial growth facto VEGF)是促成新生血管形成的重要诱生物,目前应用VEGF抑制剂治疗新生血管性眼病已受到越来越多的重视。本文对目前已经或者即将应用于眼科临床的药物,包括Macugen,Lucentis,Avastin,VEGF-trap的研究现状作一综述。

关 键 词:血管内皮生长因子抑制剂  新生血管性眼病
收稿时间:2007-08-21
修稿时间:2007-11-29

Progress of researches on anti-VEGF medication for neovascular oculopathy
Dan Chen,Ying-Chuan Fan,Li-Ying Li.Progress of researches on anti-VEGF medication for neovascular oculopathy[J].International Journal of Ophthalmology,2008,8(1):123-125.
Authors:Dan Chen  Ying-Chuan Fan  Li-Ying Li
Institution:1Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China;2Department of Ophthalmology,Sichuan Provincial Pepole’s Hospital,Chengdu 610072,Sichuan Province,China
Abstract:·Vascular endothelial growth factor(VEGF)plays a critical role in inducing neovascularization.Nowadays,application of VEGF inhibitor to treatment of neovascular eye diseases has caught more and more attention.The present paper summarized the recent advance of these anti-VEGF agents which had been used or would be used in ophthalmologic clinic,including Macugen,Lucentis,Avastin,VEGF-trap and so on..
Keywords:vascular endothelial growth factor inhibitor  neovascular eye diseases
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号